Abstract. The aim of the present study was to examine the expression and role of vascular endothelial growth factor A (VEGFA) and microRNA (miRNA or miR)-381 in tumor thrombi from patients with hepatocellular carcinoma and portal vein tumor thrombus (PVTT). Tumor thrombi and adjacent paired tissues were collected from 39 patients with hepatocellular carcinoma with PVTT. VEGFA expression levels were assessed using reverse transcription-quantitative polymerase chain reaction and western blotting. miRNAs that may regulate VEGFA expression were predicted using bioinformatics analysis and confirmed via a dual luciferase reporter assay. The effects of VEGFA and its upstream miRNA on proliferation of the proliferation of EAhy926 human venous endothelial cells were analyzed using an MTT assay. Compared with the paired adjacent tissues, VEGFA was significantly upregulated at both the mRNA and protein level in tumor thrombi (P<0.05). VEGFA was predicted to be a target of miR-381 and this was confirmed experimentally. miR-381 expression was significantly downregulated in tumor thrombi from patients with PVTT compared with paired adjacent tissues (P<0.05). In addition, transfection with antagomirs against miR-381 or short interfering RNA against VEGFA significantly inhibited EAhy926 cell proliferation (P<0.05). In conclusion, the results of the present study indicate that VEGFA is upregulated in tumor thrombi whereas miR-381 is downregulated. VEGFA is regulated by miR-381 and both may be associated with the development of PVTT.
Introduction
Primary hepatocellular carcinoma (HCC) is one of the most common malignant tumors of the digestive system, with high intrahepatic recurrence and metastasis rates leading to poor overall prognosis (1-3). Trousseau (4) reported that patients with cancer suffered complications due to venous thrombosis; the comorbidity of venous thrombosis and cancer was thus named Trousseau syndrome. Venous thrombosis is a common complication that occurs during the development of malignant tumors and is the second leading cause of death in patients with Trosseau syndrome after the cancer itself (5) . A previous study suggested that malignant tumor is a high-risk factor for venous thrombosis, with ~12.3% of patients with cancer developing thrombi within 6 months of diagnosis (6) . However, the mechanisms underlying the development of tumor thrombosis secondary to malignant tumors is yet to be elucidated.
The development of HCC is dependent on angiogenesis (7). Vascular endothelial growth factor A (VEGFA) serves an important role in the normal physiology and angiogenesis of various abnormal pathologies (8) . The expression of VEGF in HCC cells is high due to local hypoxia stimulation, particularly near tumor necrotic areas (9, 10) . Inhibiting the expression of VEGF or blocking the corresponding signal transduction pathway and other pathways has an anti-angiogenic effect (11) . Humanized monoclonal antibodies that bind to VEGFA and block its activity have been approved for the treatment of neoplastic diseases (12) .
Several mRNA and microRNA (miR or miRNA) molecules are associated with Trousseau syndrome (13), including integrin β3 and the polyphosphate-factor XII signaling pathway (14) . The occurrence of tumor thrombi is associated with neovascularization (15) . VEGF, which is also secreted by tumor cells, and its signal transduction pathway serve important roles in the development of tumor thrombosis (16) (17) (18) . In tumor angiogenesis, there are interactions between the coagulation process, inflammatory cytokines and malignant tumor growth and metastasis (19) . The high permeability of tumor neovascular tissues induces plasma leakage resulting in increased specific volume, increased blood viscosity and blood stasis, all risk factors for thrombosis (16) .
In the present study, reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blotting RNA extraction and RT-qPCR. Total RNAs were isolated from thrombi and adjacent tissues using TRIzol ® (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to the manufacturer's protocol. Following quantification using a spectrophotometer at 490 nm, RNA (1 µg) was reverse transcribed into cDNA using a TIANScript II cDNA 1st strand cDNA Synthesis kit (Tiangen Biotech Co., Ltd., Beijing, China). miRNA was reverse transcribed from total RNA using an miRcute miRNA cDNA Synthesis kit (Tiangen Biotech Co., Ltd.). qPCR was performed using the SuperReal SYBR Green PreMix (Tiangen Biotech Co., Ltd.) for mRNA, or the miRcute miRNA qPCR Detection kit (Tiangen Biotech Co., Ltd.) for miRNA using a Bio-Rad IQ5 thermocycler (Bio-Rad Laboratories, Inc., Hercules, CA, USA). For mRNA, the reaction mixture was incubated at 94˚C for 2 min followed by 35 cycles at 94˚C for 30 sec, 55˚C for 30 sec and 71˚C for 1 min. For miRNA, the reaction mixture was incubated at 95˚C for 5 min followed by 40 cycles at 95˚C for 15 sec, 60˚C for 30 sec, and 72˚C for 30 sec. Primers used were as follows: VEGFA. forward 5'-TTG CCT TGC TGC TCT ACC TC-3' and reverse 5'-AAA TGC TTT CTC CGC TCT GA-3'; β-actin, forward 5'-TGA CGT GGA CAT CCG CAA AG-3' and reverse 5'-CTG GAA GGT GGA CAG CGA GG-3'; miR-381, forward 5'-ACA CTC CAG CTG GGT ATA CAA GGG CAA GCT-3' and reverse 5'-TGG TGT CGT GGA GTC G-3'; U6, forward 5'-CTC GCT TCG GCA GCA CA-3' and reverse 5'-AAC GCT TCA CGA ATT TGC GT-3'. The relative expression levels were evaluated using the 2 -ΔΔCq method (20) . β-actin and small nuclear U6 were used as internal controls for mRNA and miRNA, respectively.
Western blotting. Proteins were extracted using radioimmunoprecipitation assay buffer and protease inhibitor phenylmethane sulfonyl fluoride. The protein concentration was determined by using a bicinchoninic acid assay kit [RTP7102; Real-Times (Beijing) Biotechnology Co., Ltd., Beijing, China]. A total of 20 µg/lane protein was separated by 10% SDS-PAGE and transferred to polyvinylidene difluoride membranes. After blocking with 5% skimmed milk at room temperature for 1 h, the membranes were probed with the rabbit anti-VEGFA (1:1,000; ab46154) or rabbit anti-β-actin (1:5,000; ab129348; both Abcam, Cambridge, MA, USA) at 4˚C overnight. After washing five times with Tris-buffered saline and Tween-20 (5 min each time), the membranes were incubated with horseradish peroxidase-conjugated goat anti-rabbit secondary antibodies (1:3,000; ab6721; Abcam) at room temperature for 1 h. Signal detection was performed using an enhanced chemiluminescence reaction kit (ab65623; Abcam) on a Gel Doc XR+ system (Bio-Rad Laboratories, Inc.). The acquired images were analyzed using Image lab 3.0 (Bio-Rad Laboratories, Inc.) and the relative protein expression was expressed as the densitometric value ratio of VEGFA to the β-actin band.
Bioinformatics analysis. To fur ther identify the miRNAs that may regulate the expression of VEGFA the following bioinformatics databases were used: miRanda (34.236.212.39/microrna/home.do), TargetScan (targetscan .org), PiTa (genie.weizmann.ac.il/pubs/mir07/mir07_data .html), RNAhybrid (bibiserv.techfak.uni-bielefeld.de/ rnahybrid/) and PICTA (pictar.mdc-berlin.de/) were used.
Dual-luciferase reporter gene assay. Based on the results of bioinformatics prediction, the conservative miR-381 binding sequence on 3'-untranslated region (UTR) of wild type (WT) or the mutant VEGFA mRNA was cloned. The primers to clone the WT miR-381 binding sequence were designed by CE Design V1.04 (Vazyme, Nanjing, China) ad follows: WT, forward 5'-tga tga aag ctg cgc act agt AAA GAG TAG GGT TTT TTT TCA GTA TTC TT-3' and reverse 5'-aaa aga tcc ttt att aag ctt TGC TGG GGA GCC AGG GGA-3'. Primers for the mutated sequence were constructed using a Mut Express II Fast Mutagenesis kit V2 C214-01/02 (Vazyme). Mutant, forward 5'-GTA CCG GTT Taa caa taA TAA AAT TCA TGT TTC CAATCTCTCTCT-3' and reverse 5'-tat tgt tAA ACC GGT ACA AAT AAG AGA GCA AG-3'. The mutant binding sequence is underlined below: 2821 tgt atc ttt tgc tct ctc ttg ctc tct tat ttg tac cgg ttt TTG TAT ata aaa ttc atg 2881 ttt cca atc tct ctc tcc ctg atc ggt gac agt cac tag ctt atc ttg aac aga tat tta Luciferase reporter plasmids were generated by inserting WT or mutant sequences of VEGFA into the multiple cloning site MTT assay. Cells were seeded into 96-well plates at a density of 2,000 cell/well. Cells were cultured at in a humidified atmosphere containing 5% CO 2 at 37˚C. At 24, 48, and 72 h, 20 µl of MTT reagent (5 mg/ml; JRDUN biotechnology, Shanghai, China) were added and cells were incubated at 37˚C for 4 h until purple precipitate was visible. On the last day the culture supernatant was removed and 150 µl dimethyl sulfoxide per well was added. The 96-well plate was oscillated for 10 min until purple precipitate was dissolved. The absorbance was measured at 490 nm on a microplate reader. A cell growth curve was generated based on these absorbance values.
Statistical analysis. Data analysis was performed using SPSS version 18.0 (SPSS, Inc., Chicago, IL, USA) and expressed as the mean standard deviation. Differences between groups were evaluated for significance using one-way analysis of variance with Student Newman Keuls, Tamhane's T2 or Dunnett's T3 post hoc tests. P<0.05 was considered to indicate a statistically significant difference.
Results

VEGFA is upregulated in tumor thrombi.
The expression of VEGFA mRNA was assessed using RT-qPCR. The results demonstrated that VEGFA mRNA expression was significantly increased in tumor thrombus samples compared with paired adjacent tissues (P<0.01; Fig. 1A ). The expression of VEGFA protein was also assessed using western blotting and the results revealed that it was significantly upregulated in tumor thrombi compared with paired adjacent tissues (P<0.05; Fig. 1B ). This suggests that VEGFA may be associated with the formation of tumor thrombi.
VEGFA is a direct target of miR-381.
Potential upstream miRNA regulators of VEGFA were investigated. miRNAs that may bind to the 3'-UTR of VEGFA were predicted using bioinformatics. An miR-381 binding site was identified at the 3'-UTR of VEGFA mRNA ( Fig. 2A) . A dual luciferase reporter assay was performed to confirm this prediction. Cotransfection of agomiR-381 and pMIR-REPORT-VEGFA WT construct significantly decreased luciferase activity compared with NC and pMIR-REPORT-VEGFA WT construct (P<0.05; Fig. 2B ). However, cotransfection with agomiR-381 and pMIR-REPORT-VEGFA mutant construct had no significant effect on luciferase activity (Fig. 2B) . These results suggest that VEGFA is a possible target of miR-381, with miR-381 binding to its 3'-UTR sequence.
To confirm the results of the dual luciferase reporter assay, EAhy926 cells were transfected with agomiR-381 or NC. AgomiR-381 transfection significantly increased miR-381 expression (P<0.01; Fig. 2C ) and significantly decreased VEGFA mRNA expression in EAhy926 cells (P<0.01; Fig. 2D ). AgomiR-381 transfection also markedly reduced VEGFA protein levels (Fig. 2E) . These results suggest that the expression of VEGFA is regulated by miR-381.
miR-381 is downregulated in tumor thrombi.
The expression of miR-381 was assessed using RT-qPCR. miR-30b expression was significantly downregulated in tumor thrombi compared with adjacent paired tissues (P<0.01; Fig. 3 ). This indicates that miR-381 may contribute to the development of PVTT.
Overexpression of miR-381 inhibits EAhy926 cell proliferation.
To investigate whether miR-381 regulates cell proliferation, EAhy926 cells were transiently transfected with agomiR-381 or NC. An MTT proliferation assay revealed that EAhy926 cells transfected with miR-381 exhibited significantly decreased cell proliferation compared with untreated cells or those transfected with NC (P<0.05; Fig. 4 ). This result suggests that miR-381 is able to inhibit the proliferation of venous endothelial cells.
Effect of VEGFA on cell proliferation. Eahy926 cell proliferation was examined following siVEGFA transfection.
siVEGFA was demonstrated to significantly decrease VEGFA expression at the mRNA (P<0.01; Fig. 5A ) and protein level (P<0.05; Fig. 5B ). siVEGFA significantly inhibited cell proliferation at 72 h post transfection compared with NC or untransfected control cells (P<0.05; Fig. 5C ). This suggests that VEGFA also serves a role in venous endothelial cell proliferation.
Discussion
In the present study, the expression of VEGFA and its upstream regulator, miR-381, was assessed in tumor thrombus and paired adjacent tissues from patients with HCC with PVTT. The association between miR-381 and VEGFA was also analyzed. The effects of miR-381 and VEGFA on venous endothelial cell proliferation were investigated and the mechanism of secondary development of PVTT in cases of HCC was discussed. To the best of our knowledge, the present study is the first to investigate the role of miR-381 and VEGF in tumor thrombosis in patients with HCC.
The 5-year survival rate of patients with HCC is <12% in the USA, ~32.5% overall and 59.1% in patients in the early stages in China (21, 22) . A number of studies have investigated the association between venous thromboembolism and malignant tumors; for example, it has been reported that almost 10% of patients with renal cell carcinoma develop venous thrombosis (23, 24) . In addition, 60% of patients with tumor thrombus have tumor metastasis (25) . For patients with tumors and venous thrombosis, complete resection of the tumor tissues is currently the only effective treatment option (24) . Venous thrombosis causes complications in patients with tumors; tumor cells are able to flow through the blood vessels to the portal vein and gradually grow to form a tumor thrombus, while the tumor cells can also spread along the vein in the liver (26, 27) .
Blocking cell signaling pathways or inhibiting tumor neovascularization to slow tumor growth is a major focus of tumor targeted therapy and the use of such neoadjuvant therapies have been described in several case studies (28-32).
In humans, VEGFA is one of the most effective angiogenic factors as it is able to promote angiogenesis and increase blood supply (33) . In the present study, it was demonstrated that VEGFA was significantly upregulated in tumor thrombi compared with normal tissues. Furthermore, silencing VEGFA inhibited EAhy926 cell proliferation. VEGF is also an important factor in HCC (34) and the data herein further suggest that VEGFA serves a crucial role in the development of PVTT.
miRNAs participate in the development of tumors by promoting the downregulation of mRNA expression and regulating protein-coding gene activity (35) (36) (37) . In the present study, miR-381 was predicted to be an upstream regulator of VEGFA, which is consistent with a previous report in MG-63 cells (38) . It has been reported that miR-381 is significantly downregulated in colon cancer tissues, and this induces the proliferation and invasion of colon cancer cells by increasing liver receptor homolog-1 upregulation (39). miRNA-381 in the p53/pituitary tumor-transforming 1 negative feedback loop inhibits the growth of pituitary tumors (40) . miR-381 is also associated with multidrug resistance gene 1 and serves a role in multiple drug resistance (41) . The combination of miR-381 and miR-424 inhibits the activity of cluster of differentiation 2 in renal cells by targeting WEE1 (42) . Furthermore, it has also been demonstrated that miR-381 is associated with lung adenocarcinoma (43) . Together, these studies demonstrate that miR-381 is a critical regulator in the development of various tumors. To further investigate the regulatory mechanism of miR-381 on VEGFA, miR-381 was overexpressed in EAhy926 cells via agomiR-381 transfection and cell proliferation was suppressed. Previous clinical studies and reports have indicated an association between tumor cell proliferation and PVTT (44) (45) (46) . Additionally, miR-381 overexpression resulted in decreased VEGFA mRNA expression. The results of a dual-luciferase reporter assay demonstrated that miR-381 is able to directly target VEGFA. Collectively, the results of the present study indicate that miR-381 is able to directly regulate VEGFA expression.
In summary, VEGFA was upregulated in tumor thrombi from patients with HCC and PVTT, whereas miR-381 was downregulated. miR-381 is able to regulate VEGFA. Furthermore, miR-381 and VEGFA may regulate the proliferation of venous endothelial cells. Therefore, the findings of the present study suggest that miR-381 and VEGFA may be associated with the development of PVTT. However, a limitation of the present study is that the sample size was relatively small and primarily made up of individuals from the Chinese population. In order to further investigate the clinical applications of miR-381 and VEGF in tumor thrombosis, transgenic mice with miR-381 or VEGF knockout should be used in future studies.
